JP2013523614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523614A5 JP2013523614A5 JP2013500523A JP2013500523A JP2013523614A5 JP 2013523614 A5 JP2013523614 A5 JP 2013523614A5 JP 2013500523 A JP2013500523 A JP 2013500523A JP 2013500523 A JP2013500523 A JP 2013500523A JP 2013523614 A5 JP2013523614 A5 JP 2013523614A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- propyl
- hydrogen
- methyl
- iso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- -1 n- propyl Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 *c(c(N1NNC(c2cc(N(*)*)cnc2)=C1)c1)ccc1[I+]* Chemical compound *c(c(N1NNC(c2cc(N(*)*)cnc2)=C1)c1)ccc1[I+]* 0.000 description 18
- YJIWDDCFWRWGHB-UHFFFAOYSA-N CC(C)c1nc(I)c(C)[o]1 Chemical compound CC(C)c1nc(I)c(C)[o]1 YJIWDDCFWRWGHB-UHFFFAOYSA-N 0.000 description 2
- CUEBVIQLPLQDJA-UHFFFAOYSA-O CC(C)/C(/[OH2+])=N/C(I)=N Chemical compound CC(C)/C(/[OH2+])=N/C(I)=N CUEBVIQLPLQDJA-UHFFFAOYSA-O 0.000 description 1
- CQRJGLBVCJVUAX-UHFFFAOYSA-O CC(C)/C(/[SH2+])=N/C(I)=N Chemical compound CC(C)/C(/[SH2+])=N/C(I)=N CQRJGLBVCJVUAX-UHFFFAOYSA-O 0.000 description 1
- SGLUBESBBHQIBA-MIEAWXDDSA-O CC(C)C(/C=C(\O)/I)=[NH2+] Chemical compound CC(C)C(/C=C(\O)/I)=[NH2+] SGLUBESBBHQIBA-MIEAWXDDSA-O 0.000 description 1
- KLXZRGNTQDXKRY-UHFFFAOYSA-O CC(C)C([NH2+]C)=CC(I)=N Chemical compound CC(C)C([NH2+]C)=CC(I)=N KLXZRGNTQDXKRY-UHFFFAOYSA-O 0.000 description 1
- POKUIYOPHXEYIK-UHFFFAOYSA-N CC(C)c1cc(I)n[n]1C Chemical compound CC(C)c1cc(I)n[n]1C POKUIYOPHXEYIK-UHFFFAOYSA-N 0.000 description 1
- NRTMMWAJFDAYKU-UHFFFAOYSA-N CC(C)c1n[o]c(I)c1 Chemical compound CC(C)c1n[o]c(I)c1 NRTMMWAJFDAYKU-UHFFFAOYSA-N 0.000 description 1
- UDHYCPAIJAAQJT-UHFFFAOYSA-N CC(C)c1nc(I)c(C)[s]1 Chemical compound CC(C)c1nc(I)c(C)[s]1 UDHYCPAIJAAQJT-UHFFFAOYSA-N 0.000 description 1
- WMJOIVQLVJFVFJ-UHFFFAOYSA-N CC(C)c1nccc(C(C)(C)C)c1 Chemical compound CC(C)c1nccc(C(C)(C)C)c1 WMJOIVQLVJFVFJ-UHFFFAOYSA-N 0.000 description 1
- IHPQEILBIOUFAC-UHFFFAOYSA-N CC(C)c1nccc(C(F)(F)F)c1 Chemical compound CC(C)c1nccc(C(F)(F)F)c1 IHPQEILBIOUFAC-UHFFFAOYSA-N 0.000 description 1
- RUBGAEMGCQLQFH-UHFFFAOYSA-N Ic1n[o]cn1 Chemical compound Ic1n[o]cn1 RUBGAEMGCQLQFH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158041.3 | 2010-03-26 | ||
| EP10158041 | 2010-03-26 | ||
| PCT/EP2011/054611 WO2011117381A1 (en) | 2010-03-26 | 2011-03-25 | B-raf kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523614A JP2013523614A (ja) | 2013-06-17 |
| JP2013523614A5 true JP2013523614A5 (enExample) | 2014-05-15 |
| JP5871896B2 JP5871896B2 (ja) | 2016-03-01 |
Family
ID=42244071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500523A Active JP5871896B2 (ja) | 2010-03-26 | 2011-03-25 | Ｂ−ｒａｆキナーゼインヒビター |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9290507B2 (enExample) |
| EP (1) | EP2552905B1 (enExample) |
| JP (1) | JP5871896B2 (enExample) |
| WO (1) | WO2011117381A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080401A1 (es) | 2006-07-07 | 2008-06-23 | Boehringer Ingelheim Int | DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS |
| CL2008001943A1 (es) * | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| TW201014860A (en) | 2008-09-08 | 2010-04-16 | Boehringer Ingelheim Int | New chemical compounds |
| EP2350052B1 (en) | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
| EP2398797B1 (en) | 2009-02-17 | 2013-11-06 | Boehringer Ingelheim International GmbH | Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases |
| US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| MX2021009535A (es) * | 2019-02-12 | 2022-10-10 | Lutris Pharma Ltd | Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. |
| CN111606887B (zh) | 2019-02-26 | 2023-03-17 | 安徽中科拓苒药物科学研究有限公司 | 一种新型激酶抑制剂 |
| WO2021035788A1 (zh) * | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | 吡唑衍生物及其用途 |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| CN116761801A (zh) * | 2021-03-12 | 2023-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU507066B1 (en) | 1977-09-06 | 1980-01-31 | Sumitomo Chemical Company, Limited | 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives |
| JPH03174153A (ja) | 1989-09-20 | 1991-07-29 | Fuji Photo Film Co Ltd | カラー画像形成方法 |
| NZ301265A (en) | 1995-02-02 | 1998-12-23 | Smithkline Beecham Plc | Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof |
| AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| EP1152759A2 (en) | 1999-02-09 | 2001-11-14 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| ATE329909T1 (de) | 2002-11-27 | 2006-07-15 | Boehringer Ingelheim Pharma | 1,2,3-triazolamid-derivate als cytokininhibitoren |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2005040152A1 (en) | 2003-10-20 | 2005-05-06 | E.I. Dupont De Nemours And Company | Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides |
| US7511042B2 (en) | 2003-12-03 | 2009-03-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | Triazole compounds |
| EP1725544B1 (en) | 2004-03-09 | 2009-05-27 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| US7485657B2 (en) | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| US7531560B2 (en) | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| JP2007076376A (ja) | 2005-09-09 | 2007-03-29 | Yanmar Co Ltd | トラクタ |
| WO2007056016A2 (en) | 2005-11-02 | 2007-05-18 | Kemia, Inc. | Bisamide cytokine inhibitors |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| JP2009536618A (ja) | 2006-04-18 | 2009-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−及び５−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体 |
| JP2009542700A (ja) | 2006-07-07 | 2009-12-03 | シェーリング コーポレイション | Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン |
| SI2041138T1 (sl) | 2006-07-07 | 2014-08-29 | Bristol-Myers Squibb Company | Pirolotriazin kinazni inhibitorji |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| PE20080401A1 (es) | 2006-07-07 | 2008-06-23 | Boehringer Ingelheim Int | DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| WO2008089034A2 (en) | 2007-01-11 | 2008-07-24 | Kemia, Inc. | Cytokine inhibitors |
| CA2692379A1 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| EP2324008B1 (en) | 2008-07-24 | 2012-05-09 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| TW201014860A (en) | 2008-09-08 | 2010-04-16 | Boehringer Ingelheim Int | New chemical compounds |
| EP2350052B1 (en) | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
| EP2398797B1 (en) | 2009-02-17 | 2013-11-06 | Boehringer Ingelheim International GmbH | Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases |
| US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
-
2011
- 2011-03-25 US US13/636,157 patent/US9290507B2/en active Active
- 2011-03-25 WO PCT/EP2011/054611 patent/WO2011117381A1/en not_active Ceased
- 2011-03-25 JP JP2013500523A patent/JP5871896B2/ja active Active
- 2011-03-25 EP EP11709962.2A patent/EP2552905B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504622A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2017524025A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| CL2013003647A1 (es) | Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos. | |
| JP2017527532A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2013526559A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2014513139A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2017519754A5 (enExample) | ||
| AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| JP2008510771A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| SI20691B (sl) | Triciklični inhibitorji poli(ADP-riboza) polimeraz | |
| MX2012001313A (es) | Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. |